| 1 |
27208730 | Hierarchical glucocorticoid-endocannabinoid interplay regulates the activation of the nucleus accumbens by insulin. | 2016 Jun |
1 |
| 2 |
22170727 | Does rimonabant independently affect free fatty acid and glucose metabolism? | 2012 Mar |
1 |
| 3 |
21564446 | Rimonabant improves cholesterol, insulin resistance and markers of non-alcoholic fatty liver in morbidly obese patients: a retrospective cohort study. | 2011 Jun |
1 |
| 4 |
20009090 | Effect of rimonabant on glycemic control in insulin-treated type 2 diabetes: the ARPEGGIO trial. | 2010 Mar |
1 |
| 5 |
19199981 | Pleiotropic effects of rimonabant: clinical implications. | 2009 |
1 |
| 6 |
19275673 | The endocannabinoid system: a promising target for the management of type 2 diabetes. | 2009 Feb |
1 |
| 7 |
18303686 | [Medication of the month. Rimonabant (Acomplia): first CB1 receptor antagonist of the endocannabinoid system]. | 2008 Jan |
1 |
| 8 |
18410553 | A comparison between rimonabant and metformin in reducing biochemical hyperandrogenaemia and insulin resistance in patients with polycystic ovary syndrome (PCOS): a randomized open-label parallel study. | 2008 Dec |
1 |
| 9 |
18417461 | Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study. | 2008 Jul |
2 |
| 10 |
18426513 | CB1 receptor blockade and its impact on cardiometabolic risk factors: overview of the RIO programme with rimonabant. | 2008 May |
1 |
| 11 |
18426514 | The endocannabinoid system and the control of glucose homeostasis. | 2008 May |
1 |
| 12 |
18551116 | The CB1 endocannabinoid system modulates adipocyte insulin sensitivity. | 2008 Aug |
3 |
| 13 |
18635590 | Modification of cardiometabolic risk through cannabinoid type-1 receptor antagonism. | 2008 Apr-May |
1 |
| 14 |
18814765 | [CB1 receptor inhibition and glucose metabolism: role of rimonabant in type 2 diabetes]. | 2008 Aug 27 |
1 |
| 15 |
17292044 | Endocannabinoid antagonism: blocking the excess in the treatment of high-risk abdominal obesity. | 2007 Feb |
2 |
| 16 |
17948364 | Reducing cardiometabolic risk through selective antagonism of CB1 receptors. | 2007 |
1 |
| 17 |
18054734 | Cannabinoid-1 receptor antagonists in type-2 diabetes. | 2007 Dec |
1 |
| 18 |
18154742 | Cannabinoid-1 receptor blockade in cardiometabolic risk reduction: efficacy. | 2007 Dec 17 |
1 |
| 19 |
18161262 | [The endocannabinoid system, overweight, and the CB1-endocannabinoid-receptor antagonist rimonabant]. | 2007 Nov 24 |
1 |
| 20 |
18194939 | Role of the endocannabinoid system in management of patients with type 2 diabetes mellitus and cardiovascular risk factors. | 2007 Nov-Dec |
1 |
| 21 |
15836887 | Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. | 2005 Apr 16-22 |
1 |